TC BioPharm (Holdings) (FRA:T0U) Research & Development: €6.42 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T0U TC BioPharm (Holdings) PLC FRA:T0U
17 GF Score
Price €132.00
View Full Analysis

What is TC BioPharm (Holdings) Research & Development?

TC BioPharm (Holdings) FRA:T0U 17 Research & Development is €6.42 Mil as of Dec. 2024. GuruFocus rates FRA:T0U with a GF Score™ of 17/100.

Research & Development is the aggregate amount of research and development expenses during the year. TC BioPharm (Holdings)'s Research & Development for the six months ended in Dec. 2024 was €3.78 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €6.42 Mil.

TC BioPharm (Holdings)  (FRA:T0U) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TC BioPharm (Holdings) Research & Development Related Terms

TC BioPharm (Holdings) Research & Development Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) Research & Development Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 7.38 7.25 8.73 9.02 6.48

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 4.71 4.33 2.65 3.78
FRA:T0U
17GF Score
TC BioPharm (Holdings) PLC FRA:T0U
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TC BioPharm (Holdings) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €6.42 Mil mean?
TC BioPharm (Holdings) (FRA:T0U) has a Research & Development of €6.42 Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on TC BioPharm (Holdings) and its competitors.
Is TC BioPharm (Holdings)'s Research & Development too high?
TC BioPharm (Holdings)'s current Research & Development is €6.42 Mil. Overall, TC BioPharm (Holdings) has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does TC BioPharm (Holdings)'s Research & Development compare to SIGY and CNBX?
TC BioPharm (Holdings)'s Research & Development of €6.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TC BioPharm (Holdings) and its competitors. TC BioPharm (Holdings)'s current Research & Development is €6.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (FRA:T0U) has a current Research & Development of €6.42 Mil. The current Research & Development is €6.42 Mil. TC BioPharm (Holdings)'s overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TC BioPharm (Holdings) (FRA:T0U), the current Research & Development is €6.42 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
17GF Score

Get the complete analysis for FRA:T0U

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€132.00
Price